Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

OBJECTIVE: Fenfluramine, which was previously approved as a weight loss drug, was withdrawn in 1997 when reports of cardiac valvulopathy emerged. The present study was conducted in part to characterize the cardiovascular safety profile of low‐dose fenfluramine when used in a pediatric population to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Wyman W., Galer, Bradley S., Wong, Pierre C., Farfel, Gail, Pringsheim, Milka, Keane, Martin G., Agarwal, Anupam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754414/
https://www.ncbi.nlm.nih.gov/pubmed/32809271
http://dx.doi.org/10.1111/epi.16638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754414/
https://www.ncbi.nlm.nih.gov/pubmed/32809271
http://dx.doi.org/10.1111/epi.16638

Ejemplares similares